Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 415-421, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vermes, I.
Right arrow Articles by Schoemaker, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vermes, I.
Right arrow Articles by Schoemaker, J.

Clinical Chemistry, Vol 37, 415-421, Copyright © 1991 by American Association for Clinical Chemistry

Interpretations of five monoclonal immunoassays of lutropin and follitropin: effects of normalization with WHO standard

I Vermes, HA Bonte, G v. d. Sluijs Veer and J Schoemaker
Department of Clinical Chemistry, Medisch Spectrum Twente, Enschede, The Netherlands.

Five mono(oligo)clonal immunometric assays for lutropin (LH) and follitropin (FSH)--bioMerieux, IRE-Medgenix, Serono Diagnostics, Diagnostics Products Corp. (DPC), and LKB--were evaluated in comparison with two polyclonal RIAs (DPC and Amersham). Detection limits varied from 0.04 to 0.32 int. unit/L and 0.06 to 0.86 int. unit/L for LH and FSH, respectively. Intra- and interassay precision (CV) at three concentrations varied from 2.0% to 29.8%, showing that not all kits tested gave acceptable results, especially for LH. Linearity and parallelism were acceptable, except for the DPC FSH kit and the bioMerieux LH kit. High-dose "hook" effects were seen in some kits at LH concentrations of 250 int. units/L, but not in the FSH kits up to concentrations of 350 int. units/L. Reagents in some kits cross-reacted with choriogonadotropin. The clinical validity of the assays was tested in 25 pre- and 25 postmenopausal healthy women and in 66 patients with polycystic ovary disease. In contrast to FSH, LH values varied significantly not only between polyclonal and monoclonal assays but also between the various monoclonal assays, despite the fact that all manufacturers state that their kits are calibrated on the same standards: WHO International Reference Preparation (IRP) 68/40 for LH and 78/549 for FSH. We normalized the results by using new WHO standards: IRP 80/552 for LH and IRP 83/575 for FSH. This decreased significantly the between-kit differences in LH results for individuals. The much-used LH/FSH ratio greater than 3 for diagnosing patients with polycystic ovary disease is not valid when monoclonal assays are used, and is kit-dependent. However, using the normalized results yields a "new" LH/FSH ratio, which is kit-independent and differs significantly between patients and healthy subjects.


The following articles in journals at HighWire Press have cited this article:


Home page
 Hum ReprodHome page
A. Olivares, M. Cardenas, C. Timossi, T. Zarinan, V. Diaz-Sanchez, and A. Ulloa-Aguirre
Reactivity of different LH and FSH standards and preparations in the World Health Organization matched reagents for enzyme-linked immunoassays of gonadotrophins
Hum. Reprod., November 1, 2000; 15(11): 2285 - 2291.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. P. Rose, R. E. Gaines Das, and A. H. Balen
Definition and Measurement of Follicle Stimulating Hormone
Endocr. Rev., February 1, 2000; 21(1): 5 - 22.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.